Evidence map›Paper›PMID 32293552›Full record

ArticleBiological research2020

Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.

Patricia García, Carolina Bizama, Lorena Rosa, Jaime A Espinoza, Helga Weber, Javier Cerda-Infante, Marianela Sánchez, Viviana P Montecinos, Justo Lorenzo-Bermejo, Felix Boekstegers and 9 more

Open access · goldAbstract read
In one paragraph

Article in Biological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Whole-exome sequencing identifies cancer-associated variants of the endo-lysosomal ion transport channels in the Saudi population.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Patricia GarcíaDepartment of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Carolina BizamaDepartment of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Lorena RosaDepartment of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Jaime A EspinozaScience for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Helga WeberCenter of Excellence in Translational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile.
Javier Cerda-InfanteDepartment of Hematology Oncology; Cellular and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile.
Marianela SánchezDepartment of Hematology Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile.
Viviana P MontecinosDepartment of Hematology Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile.
Justo Lorenzo-BermejoStatistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Felix BoekstegersStatistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Marcela Dávila-LópezBioinformatics Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Francisca AlfaroDepartment of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Claudia Leiva-AcevedoDepartment of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Zasha ParraCytogenetics Laboratory, Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
Diego RomeroDepartment of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Sumie KatoDivision of Obstetrics and Gynecology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Pamela LealCenter of Excellence in Translational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile.
Marcela LagosDepartment of Clinical Laboratory, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Juan Carlos RoaDepartment of Pathology, Faculty of Medicine, Millennium Institute of Immunology and Immunotherapy, Pontificia Universidad Católica de Chile, Santiago, Chile. jcroa@med.puc.cl.ORCID http://orcid.org/0000-0001-8313-8774
Pontificia Universidad Católica de Chile · CLUniversidad de La Frontera · CLHeidelberg University · DEComplejo Asistencial Sótero del Río · CLScience for Life Laboratory · SEUniversity of Gothenburg · SE

Funding

Comisión Nacional de Investigación Científica y Tecnológica 21140027Dirección de Investigación Medicina-UC (CL) 16-240Fondo Nacional de Desarrollo Científico y Tecnológico 11180987Fondo Nacional de Desarrollo Científico y Tecnológico 1151008Fondo Nacional de Desarrollo Científico y Tecnológico 1160800Fondo Nacional de Desarrollo Científico y Tecnológico 1170893Fondo Nacional de Desarrollo Científico y Tecnológico 1171463Instituto Milenio IMII P09/016-F
6 · The paper itself

Abstract

backgroundGallbladder cancer (GBC) is the most common tumor of the biliary tract. The incidence of GBC shows a large geographic variability, being particularly frequent in Native American populations. In Chile, GBC represents the second cause of cancer-related death among women. We describe here the establishment of three novel cell lines derived from the ascitic fluid of a Chilean GBC patient, who presented 46% European, 36% Mapuche, 12% Aymara and 6% African ancestry.

resultsAfter immunocytochemical staining of the primary cell culture, we isolated and comprehensively characterized three independent clones (PUC-GBC1, PUC-GBC2 and PUC-GBC3) by short tandem repeat DNA profiling and RNA sequencing as well as karyotype, doubling time, chemosensitivity, in vitro migration capability and in vivo tumorigenicity assay. Primary culture cells showed high expression of CK7, CK19, CA 19-9, MUC1 and MUC16, and negative expression of mesothelial markers. The three isolated clones displayed an epithelial phenotype and an abnormal structure and number of chromosomes. RNA sequencing confirmed the increased expression of cytokeratin and mucin genes, and also of TP53 and ERBB2 with some differences among the three cells lines, and revealed a novel exonic mutation in NF1. The PUC-GBC3 clone was the most aggressive according to histopathological features and the tumorigenic capacity in NSG mice.

conclusionsThe first cell lines established from a Chilean GBC patient represent a new model for studying GBC in patients of Native American descent.

Indexed as

AnimalsAntigens, Tumor-Associated, CarbohydrateAntineoplastic AgentsAscitic FluidCarcinogenesisCarcinogenicity TestsCell Line, TumorChileCisplatinClone CellsDeoxycytidineDNA FingerprintingEpithelial CellsErb-b2 Receptor Tyrosine KinasesGallbladder NeoplasmsGemcitabineAntigens, Tumor-Associated, CarbohydrateAntineoplastic AgentsCisplatinDeoxycytidineErb-b2 Receptor Tyrosine KinasesGemcitabineKeratin-19Keratin-7Tumor Suppressor Protein p53AscitesCancer cell linesGallbladder cancerGene expression profileNative American ancestry

Identifiers

PMID32293552
PMCPMC7158131
OpenAlexW3016034256

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.